Pages that link to "Q52059159"
Jump to navigation
Jump to search
The following pages link to Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. (Q52059159):
Displaying 50 items.
- Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients (Q24645597) (← links)
- The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation (Q24678674) (← links)
- Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. (Q24813543) (← links)
- Molecular substratification of bladder cancer: moving towards individualized patient management (Q26744343) (← links)
- Toxin-based targeted therapy for malignant brain tumors (Q27006226) (← links)
- Sulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach (Q30234740) (← links)
- Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer (Q30438089) (← links)
- The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence (Q30845020) (← links)
- Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer (Q33428194) (← links)
- Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer (Q33554443) (← links)
- Human epidermal growth factor receptor 2 expression is more important than Bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer (Q33648897) (← links)
- Human epidermal growth factor receptor 2 expression in urothelial carcinoma of the renal pelvis: correlation with clinicopathologic parameters (Q33802832) (← links)
- Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas (Q33846990) (← links)
- Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer (Q33874421) (← links)
- Expression of NRG1 and its receptors in human bladder cancer (Q34745805) (← links)
- Urothelial carcinomas: a focus on human epidermal receptors signaling (Q35172558) (← links)
- HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells (Q35201923) (← links)
- The anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition (Q35571641) (← links)
- Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report (Q35993293) (← links)
- Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis (Q36238822) (← links)
- Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma (Q36267685) (← links)
- High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues (Q36421306) (← links)
- Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer (Q36511054) (← links)
- Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma (Q36611021) (← links)
- Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder (Q36615866) (← links)
- Growth factors and receptors as prognostic markers in urothelial carcinoma (Q37119228) (← links)
- ErbB3 is required for ductal morphogenesis in the mouse mammary gland (Q37131318) (← links)
- Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer (Q37186967) (← links)
- Targeted therapies in the management of metastatic bladder cancer (Q37290448) (← links)
- Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family (Q37316604) (← links)
- Molecular targets and targeted therapies in bladder cancer management. (Q37336643) (← links)
- Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature (Q37399112) (← links)
- Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion (Q37588340) (← links)
- Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer. (Q37662229) (← links)
- Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experience (Q37665453) (← links)
- Role of anti-Her-2 therapy in bladder carcinoma (Q37704982) (← links)
- When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression (Q37933675) (← links)
- Prognostic value of cell-cycle regulation biomarkers in bladder cancer. (Q38049692) (← links)
- HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. (Q38735527) (← links)
- Template-driven gene selection procedure (Q38785200) (← links)
- Expression of nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues (Q39788150) (← links)
- Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations (Q39863683) (← links)
- p-Benzoquinone initiates non-invasive urothelial cancer through aberrant tyrosine phosphorylation of EGFR, MAP kinase activation and cell cycle deregulation: Prevention by vitamin C. (Q41678957) (← links)
- Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer (Q46851166) (← links)
- Evaluation of Protein Levels of the Receptor Tyrosine Kinase ErbB3 in Serum. (Q46942173) (← links)
- Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer (Q49909762) (← links)
- Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients (Q50753687) (← links)
- Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups (Q50931074) (← links)
- Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies. (Q55081994) (← links)
- A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0 (Q56538422) (← links)